Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00271
|
|||||
| Drug Name |
Empagliflozin
|
|||||
| Synonyms |
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; 864070-44-0; AK160980; BI 10773; BI-10773; BI10773; CHEBI:82720; Empagliflozin (BI 10773); HDC1R2M35U; JARDIANCE; UNII-HDC1R2M35U
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 1 diabetes [ICD11: 5A10] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H27ClO7
|
|||||
| Canonical SMILES |
C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
|
|||||
| InChI |
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
|
|||||
| InChIKey |
OBWASQILIWPZMG-QZMOQZSNSA-N
|
|||||
| CAS Number |
CAS 864070-44-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 450.9 | Topological Polar Surface Area | 109 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
135267035
, 136350032
, 137759455
, 160647541
, 160671533
, 162201844
, 163620871
, 170500874
, 172232552
, 17390987
, 178101464
, 186021010
, 189024748
, 198945623
, 206246269
, 211535427
, 223447440
, 223471392
, 223602217
, 223701070
, 227166637
, 23917761
, 241383513
, 242077478
, 245606277
, 249737155
, 249865857
, 251963060
, 252067199
, 252159682
, 252215347
, 35020536
, 80625411
|
|||||
| ChEBI ID |
ChEBI:82720
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Empagliflozin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) | |||||
| 3 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.